BLAINJECTIONINJECTABLE
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
20
Intelligence
6/8 — Comprehensive
BILPREVDA (denosumab) by Novartis is rank ligand blocking activity [moa]. Approved for skeletal-related events in patients with multiple myeloma, skeletally mature adolescents with giant cell tumor of bone, where surgical resection is likely to result in severe morbidity [see clinical trials ( )] and 3 more indications. First approved in 2025.
Mechanism of Action
RANK Ligand Blocking Activity
Pharmacologic Class:
RANK Ligand Inhibitor
Worked on BILPREVDA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.